Business Wire

CA-GRINDR

20.11.2023 10:08:56 CET | Business Wire | Press release

Share
Grindr Brings Free At-Home HIV Self-Test Kits to Europe for the First Time With New Programs in Georgia and Ireland

At the outset of European testing week, Grindr Inc. (NYSE: GRND), the world’s largest social network for the LGBTQ+ community, today announced the launch of its new partnerships with Equality Movement and MPOWER to connect Grindr users directly with HIV self-test kits in Georgia and Ireland, respectively. With these partnerships, Georgia and Ireland become the first countries outside of the United States in which Grindr users can order free at-home HIV self-test kits directly from links embedded in the Grindr interface, in less than one minute.

Access to HIV testing continues to be one of the biggest obstacles in the fight against the global HIV epidemic. In-person testing, in particular, poses barriers such as clinic operating hours, transportation, costs, and concerns about privacy or stigma. These barriers become even more pronounced for a variety of Grindr users, such as those living in rural areas, or those who are not “out” to their families. At-home self-testing offers users a convenient and discrete option to protect their health.

Grindr has a long history of promoting both Equality Movement and MPOWER’s home self-testing programs. As it became clear that a significant number of Grindr users needed the level of flexibility and anonymity that home self-testing provides, Grindr decided to partner with both organizations to make this easier than ever. In expanding this collaboration, Grindr emphasizes both organizations’ commitment to implementing community-level interventions and judgment-free resources.

“For the past eight years, it has been my goal to find ways to increase access to HIV testing for Grindr users, and of all the things we’ve experimented with, embedding in-app links to home self-test kits has emerged as the most powerful strategy by a considerable margin,” said Jack Harrison-Quintana, Director of Grindr For Equality. “I could not be more excited to launch partnerships similar to those with Equality Movement and MPOWER around the world.”

“Making free at-home HIV self-testing available directly through the Grindr app helps to ensure members of the LGBTQ+ community have access to vital services they need to protect their health and feel supported in their daily lives,” said Lasha Nonikashvili at Equality Movement. “We are thrilled that the LGBTQ+ community across Georgia will now be able to protect their health with an easy solution they can access from home.”

“This partnership with Grindr has the potential to revolutionize the way our community across Ireland accesses vital at-home HIV self-testing,” said Adam Shanley at MPOWER, whose mission is to devise sex-positive, judgment-free and harm reduction-based resources, services and support for gay, bisexual and MSM in Ireland. “By making these resources more widely available at home, we hope to increase access, reduce stigma, and contribute to the long-term reduction of HIV.”

Today’s announcement builds on Grindr’s commitment to achieving a meaningful impact for the LGBTQ+ community. Earlier this year, we partnered with Building Healthy Online Communities and Emory University to launch Together TakeMeHome (TTMH) with support from the U.S. Centers for Disease Control and Prevention. TTMH is a unique partnership that has distributed over 232,262 test kits within the first six months of the program. Nearly a quarter of those orders were placed by people who had never previously tested for HIV, and a majority were requested through Grindr. Grindr remains committed to launching similar programs for users around the world.

About Grindr Inc.

With more than 13 million monthly active users in virtually every country in the world, Grindr has grown to become a fundamental part of the LGBTQ+ community since its launch in 2009. The company continues to expand its ecosystem to enable gay, bi, trans, and queer people to connect, express themselves, and discover the world around them. Grindr’s impact is further driven by Grindr for Equality’s wide-ranging initiatives that help the LGBTQ+ community around the world. Grindr is headquartered in West Hollywood, California. The Grindr app is available on the App Store and Google Play.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120646279/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye